Last reviewed · How we verify

Mercury Toxicity — Treatment Landscape & Competitive Intelligence

Mercury Toxicity (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Mercury Toxicity, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Bal DIMERCAPROL Provepharm Sas alpha-Adrenergic Agonist [EPC] 1946-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Mercury Toxicity
  2. Provepharm Sas · 1 drug in Mercury Toxicity

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Mercury Toxicity:

Cite this brief

Drug Landscape (2026). Mercury Toxicity — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/mercury-toxicity. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing